Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.95
(3.15%)
SEK 2.95
(3.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -44.61 Million SEK | -6.78% |
| 2022 | -41.78 Million SEK | -46.37% |
| 2021 | -28.54 Million SEK | -19.43% |
| 2020 | -23.9 Million SEK | 3.32% |
| 2019 | -24.72 Million SEK | -51.3% |
| 2018 | -16.33 Million SEK | -86.61% |
| 2017 | -8.75 Million SEK | -11.74% |
| 2016 | -7.83 Million SEK | -1094.53% |
| 2015 | -656 Thousand SEK | -3180.0% |
| 2014 | -20 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.76 Million SEK | 14.41% |
| 2024 Q1 | -7.9 Million SEK | 42.49% |
| 2023 Q1 | -10.34 Million SEK | 19.36% |
| 2023 Q3 | -12.98 Million SEK | -65.9% |
| 2023 Q2 | -7.82 Million SEK | 24.34% |
| 2023 FY | -44.61 Million SEK | -6.78% |
| 2023 Q4 | -13.74 Million SEK | -5.86% |
| 2022 Q3 | -8.14 Million SEK | 25.36% |
| 2022 Q4 | -12.83 Million SEK | -57.46% |
| 2022 FY | -41.78 Million SEK | -46.37% |
| 2022 Q1 | -10.93 Million SEK | -35.83% |
| 2022 Q2 | -10.91 Million SEK | 0.19% |
| 2021 Q3 | -8.23 Million SEK | -51.16% |
| 2021 FY | -28.54 Million SEK | -19.43% |
| 2021 Q4 | -8.05 Million SEK | 2.25% |
| 2021 Q1 | -5.99 Million SEK | 50.63% |
| 2021 Q2 | -5.45 Million SEK | 9.08% |
| 2020 FY | -23.9 Million SEK | 3.32% |
| 2020 Q2 | -1.86 Million SEK | 59.4% |
| 2020 Q1 | -4.59 Million SEK | 37.88% |
| 2020 Q3 | -4.85 Million SEK | -160.32% |
| 2020 Q4 | -12.14 Million SEK | -150.07% |
| 2019 Q3 | -7.7 Million SEK | -85.97% |
| 2019 Q4 | -7.39 Million SEK | 3.98% |
| 2019 FY | -24.72 Million SEK | -51.3% |
| 2019 Q1 | -4.55 Million SEK | 32.83% |
| 2019 Q2 | -4.14 Million SEK | 9.13% |
| 2018 Q2 | -3.14 Million SEK | -4.03% |
| 2018 FY | -16.33 Million SEK | -86.61% |
| 2018 Q4 | -6.78 Million SEK | -100.54% |
| 2018 Q3 | -3.38 Million SEK | -7.53% |
| 2018 Q1 | -3.02 Million SEK | 3.87% |
| 2017 Q3 | -2.16 Million SEK | -15.87% |
| 2017 Q1 | -1.58 Million SEK | 17.16% |
| 2017 Q2 | -1.86 Million SEK | -17.74% |
| 2017 FY | -8.75 Million SEK | -11.74% |
| 2017 Q4 | -3.14 Million SEK | -45.57% |
| 2016 Q1 | -2.71 Million SEK | -488.27% |
| 2016 FY | -7.83 Million SEK | -1094.53% |
| 2016 Q4 | -1.91 Million SEK | -71.34% |
| 2016 Q3 | -1.11 Million SEK | 68.16% |
| 2016 Q2 | -3.5 Million SEK | -29.15% |
| 2015 FY | -656 Thousand SEK | -3180.0% |
| 2015 Q2 | -401 Thousand SEK | 36.75% |
| 2015 Q3 | -320 Thousand SEK | 20.2% |
| 2015 Q4 | 699 Thousand SEK | 318.44% |
| 2015 Q1 | -634 Thousand SEK | 0.0% |
| 2014 FY | -20 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -225.856% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | -20.034% |
| BioGaia AB (publ) | 365.35 Million SEK | 112.211% |
| Enzymatica AB (publ) | -49.72 Million SEK | 10.286% |
| Gabather AB (publ) | -9.43 Million SEK | -372.746% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | -24.673% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -111.506% |
| Nanexa AB (publ) | -76.39 Million SEK | 41.604% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -189.601% |
| ODI Pharma AB | 355.97 Thousand SEK | 12632.763% |
| Orexo AB (publ) | -128.3 Million SEK | 65.228% |
| Probi AB (publ) | 16.81 Million SEK | 365.254% |
| Swedencare AB (publ) | 58.6 Million SEK | 176.131% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 101.852% |
| Toleranzia AB | -7.45 Million SEK | -498.11% |
| Vivesto AB | -367.03 Million SEK | 87.845% |